Orchestra BioMed Holdings, Inc. (OBIO) Stock Score, Valuation & Financial Research
Orchestra BioMed Holdings, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 29/100.
Quick answer for OBIO
Orchestra BioMed Holdings, Inc. currently has a Wall Street Score of 29/100. The stored market price is $6.12. Its financial score is 25/100. Its valuation score is 0/100. These figures are a research snapshot, not a buy or sell recommendation.
What Orchestra BioMed Holdings, Inc. does
Orchestra BioMed Holdings, Inc. operates as an innovative company in the biomedical sector. Its leading product candidates are BackBeat Cardiac Neuromodulation Therapy (CNT), designed to manage hypertension, and the Virtue Sirolimus AngioInfusion Balloon (SAB), aimed at treating atherosclerotic artery disease. The company's offerings also encompass FreeHold retractors, which are solutions for minimally invasive surgical procedures. Orchestra BioMed has formed key alliances to advance its products: a strategic collaboration with Medtronic focuses on developing and commercializing BackBeat CNT for pacemaker-indicated patients suffering from hypertension. Additionally, a partnership with Terumo Corporation is dedicated to the development and market introduction of Virtue SAB for artery disease. The company's headquarters are located in New Hope, Pennsylvania.
OBIO financial snapshot
- Wall Street Score:
- 29/100
- Current price:
- $6.12
- Market capitalization:
- $366.5M
- Revenue:
- $32.7M
- Net income:
- $-54.6M
- Free cash flow:
- $-49.5M
- Cash:
- $28.4M
- Total debt:
- $33.6M
- EPS:
- -1.38
- Financial score:
- 25/100
- Valuation score:
- 0/100
- Revenue score:
- 22/100
What stands out
- Reported year-over-year revenue growth is -0.0%.
- Free cash flow is $-49.5M, showing cash burn in the current stored period.
- The balance sheet shows $28.4M of cash versus $33.6M of total debt, so leverage deserves attention.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 25/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-07-24.
How to research OBIO
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.